Prevalence and Mortality due to COVID-19 in HIV Co-Infected Population: A Systematic Review and Meta-Analysis.

COVID-19 HIV Meta-analysis Prevalence Prognosis Systematic review

Journal

Infectious diseases and therapy
ISSN: 2193-8229
Titre abrégé: Infect Dis Ther
Pays: New Zealand
ID NLM: 101634499

Informations de publication

Date de publication:
Sep 2021
Historique:
received: 10 02 2021
accepted: 09 04 2021
pubmed: 4 5 2021
medline: 4 5 2021
entrez: 3 5 2021
Statut: ppublish

Résumé

The coronavirus disease 2019 (COVID-19) was defined as a species of beta coronavirus causing atypical respiratory disease in humans. The COVID-19 pandemic has resulted in an unprecedented health and economic crisis worldwide. Little is known about the specifics of its influence on people living with human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) (PLWHA). In this study, we aim to investigate the prevalence and mortality in PLWHA co-infected with COVID-19. The databases PUBMED, EMBASE, BioRxiv, and medRxiv were searched up to 9 March 2021 to explore the prevalence and mortality rate of COVID-19 in PLWHA. Cohort studies and case series meeting the inclusion criteria were included in this review. We identified 14 eligible studies, 9 of which were cohort and 5 were case series. A total of 203,761 patients with COVID-19 were identified (7718 PLWHA vs. 196,043 non-PLWHA). Meta-analyses estimated the prevalence and mortality rate of COVID-19 in PLWHA was 0.774% [95% confidence interval (CI) 0.00393-0.01517] and 8.814% (95% CI 0.05766-0.13245) respectively. COVID-19 co-infected PLWHA do not seem to be associated with higher mortality, as compared to non-PLWHA [relative risk (RR) 0.96 (95% CI 0.88-1.06)]. The presence of comorbidities such as diabetes mellitus, RR 5.2 (95% CI 4.25-6.36), hypertension and chronic cardiac disease, RR 4.2 (95% CI 1.09-16.10), and chronic kidney disease, RR 8.43 (95% CI 5.49-12.93) were associated with an increased mortality in COVID-19 co-infected PLWHA. The estimated prevalence and mortality rate of COVID-19 in PLWHA were 0.774% and 8.814%, respectively. Since most of the included studies used unmatched populations, comparisons between PLWHA and non-PLWHA should be interpreted with caution. Further investigations are needed for a more comprehensive understanding of the relationship between cluster of differentiation 4 cell count, HIV viral load, antiretroviral therapy, and COVID-19 related prognosis in PLWHA.

Identifiants

pubmed: 33939121
doi: 10.1007/s40121-021-00447-1
pii: 10.1007/s40121-021-00447-1
pmc: PMC8091145
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1267-1285

Informations de copyright

© 2021. The Author(s).

Références

AIDS. 2020 Nov 1;34(13):F3-F8
pubmed: 32796217
AIDS. 2020 Oct 1;34(12):1789-1794
pubmed: 32675581
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Lancet HIV. 2020 Aug;7(8):e554-e564
pubmed: 32473657
Lancet HIV. 2021 Jan;8(1):e24-e32
pubmed: 33316211
J Med Virol. 2021 Feb;93(2):726-732
pubmed: 32692406
Life Sci. 2020 Jul 15;253:117592
pubmed: 32222463
Clin Infect Dis. 2021 Oct 5;73(7):e2095-e2106
pubmed: 33095853
Clin Infect Dis. 2021 Oct 5;73(7):e2005-e2015
pubmed: 32860699
J Med Virol. 2021 Mar;93(3):1687-1693
pubmed: 32949148
AIDS. 2021 Mar 15;35(4):F1-F10
pubmed: 33587448
J Clin Pharmacol. 2021 May;61(5):581-590
pubmed: 33217030
Lancet. 2018 Nov 10;392(10159):1736-1788
pubmed: 30496103
Stat Med. 2002 Jun 15;21(11):1539-58
pubmed: 12111919
AIDS. 2020 Oct 1;34(12):1781-1787
pubmed: 32604138
J Med Virol. 2021 Jan;93(1):59-60
pubmed: 32497253
AIDS Patient Care STDS. 2020 Jun;34(6):247-248
pubmed: 32407127
Nature. 2019 Jun;570(7760):189-193
pubmed: 31092927
Clin Infect Dis. 2021 Oct 5;73(7):e2086-e2094
pubmed: 32803216
Int J STD AIDS. 2021 Apr;32(5):435-443
pubmed: 33533294
JAMA Netw Open. 2021 Feb 1;4(2):e2037069
pubmed: 33533933
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
AIDS. 2020 Oct 1;34(12):1771-1774
pubmed: 32773476
J Infect Public Health. 2020 Dec;13(12):1856-1861
pubmed: 33168456
Clin Infect Dis. 2020 Dec 31;71(11):2933-2938
pubmed: 32594164
Lancet HIV. 2020 Jul;7(7):e514-e520
pubmed: 32473102
AIDS Behav. 2021 Jan;25(1):85-92
pubmed: 32734438
Infection. 2020 Oct;48(5):681-686
pubmed: 32394344
Am J Epidemiol. 2021 Jan 4;190(1):10-16
pubmed: 32696057
AIDS Behav. 2021 Jan;25(1):68-72
pubmed: 32816193
J Clin Epidemiol. 2009 Oct;62(10):e1-34
pubmed: 19631507
AIDS Care. 2016;28(2):160-9
pubmed: 26565754
JBI Evid Synth. 2020 Oct;18(10):2127-2133
pubmed: 33038125
J Nurs Res. 2007 Sep;15(3):202-14
pubmed: 17806037
J Med Virol. 2021 Apr;93(4):2385-2395
pubmed: 33331656
AIDS. 2020 Nov 1;34(13):1983-1985
pubmed: 32796214
J Med Virol. 2021 Feb;93(2):1145-1149
pubmed: 32706409
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120
Ann Intern Med. 2020 Oct 6;173(7):536-541
pubmed: 32589451

Auteurs

Min Liang (M)

Department of Respiratory and Critical Care Medicine, Maoming People's Hospital, Maoming, China. imtuaska@163.com.

Ning Luo (N)

Department of Respiratory and Critical Care Medicine, Maoming People's Hospital, Maoming, China.

Mafeng Chen (M)

Department of Otolaryngology, Maoming People's Hospital, Maoming, China.

Chunna Chen (C)

Department of Dermatology, Maoming People's Hospital, Maoming, China.

Shivank Singh (S)

Southern Medical University, Guangzhou, China.

Shantanu Singh (S)

Division of Pulmonary, Critical Care and Sleep Medicine, Marshall University, Huntington, USA.

Shifan Tan (S)

Department of Respiratory and Critical Care Medicine, Maoming People's Hospital, Maoming, China. mmrytsf@163.com.

Classifications MeSH